Data Collection for Echocardiography-Based Software Assessment
Launched by ANUMANA, INC. · Aug 10, 2025
Trial Information
Current as of September 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical study is looking at how well a new computer program works by using information gathered during regular heart procedures. Specifically, it focuses on patients who are having a common treatment called left atrial appendage closure, which helps reduce the risk of stroke in people with an irregular heartbeat known as atrial fibrillation. The study does not involve any new treatments or extra tests—only data from usual care is collected.
If you are between 65 and 74 years old and are scheduled for this standard heart procedure, you might be eligible to participate. To join, you simply need to agree to let researchers use your medical information, which is kept private and secure. Being part of the study won’t change your treatment or add any extra steps; it just helps doctors understand if the new software can assist in analyzing heart images better in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing a standard left atrial appendage closure procedure with associated imaging.
- Exclusion Criteria:
- • Did not provide authorization to use data for research purposes.
About Anumana, Inc.
Anumana, Inc. is an innovative biotechnology company dedicated to advancing cardiovascular care through the integration of artificial intelligence and machine learning with clinical diagnostics. By harnessing the power of data analytics, Anumana aims to enhance the accuracy and efficiency of cardiovascular disease detection and management. The company is committed to developing cutting-edge solutions that facilitate early intervention and personalized treatment pathways, ultimately improving patient outcomes and transforming the landscape of cardiac health. With a focus on rigorous clinical trials and collaborations with leading healthcare institutions, Anumana is at the forefront of redefining the future of cardiovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
New Bedford, Massachusetts, United States
Amherst, New York, United States
Patients applied
Trial Officials
Leon Ptaszek, MD, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported